(Dasacine)Dasatinib

Aug 26, 2021

10 likes | 24 Vues

Dasacine (Dasatinib) comes with the strength of 50mg and is used for the treatment of Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia.

Share Presentation

Embed Code

Link

arecharh

Télécharger la présentation

(Dasacine)Dasatinib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

(Dasacine)Dasatinib www.arechar.in Contact Us: +91 11 435679 567 Email Us: info@arechar.in

FDA’s Oncologic Drugs Advisory Committee Meeting

FDA’s Oncologic Drugs Advisory Committee Meeting. DASATINIB (BMS-354825). 2 June 2006. Donna Morgan Murray, PhD Bristol-Myers Squibb Global Regulatory Sciences. Introduction. BMS Presentation. Introduction . ……………….. Donna Morgan Murray, PhD BMS, Global Regulatory Sciences

879 views • 65 slides

Phase II Study of Dasatinib in Advanced Sarcomas SARC 009

Phase II Study of Dasatinib in Advanced Sarcomas SARC 009. Study PI: Scott Schuetze Registration and eCRF: CRAB Drug supply: BMS. Dasatinib. Small molecule inhibitor of src-family kinases (src, bcr-abl) and PDGFR Oral dosing Short half-life

312 views • 12 slides

Phase II Study of Dasatinib (BMS-354825) in Advanced Sarcomas and Chordoma

Phase II Study of Dasatinib (BMS-354825) in Advanced Sarcomas and Chordoma. Coordinating Center: U Michigan. Probability of response to imatinib (95% posterior credible intervals). Rationale for trial: extension of results from imatinib in sarcoma.

388 views • 18 slides

Supplementary Figure S3

Supplementary Figure S3. Analysis of mTOR and AKT signaling in breast cancer cell lines treated with dasatinib and rapamycin. MCF7. MDA-MB-231. BT474. 1hr. 24hr. 1hr. 24hr. 1hr. 24hr. Combo. Combo. Combo. Combo. Combo. Combo. DMSO. DMSO. DMSO. DMSO. DMSO. DMSO. Rap.

172 views • 1 slides

Toxicité

Traitements ciblés associés au docétaxel dans les CPRCm : un concept à revoir après 8 essais de phase III négatifs (1). Étude de phase III READY : docétaxel + dasatinib versus placebo.

148 views • 3 slides

Supplementary Figure S7

Supplementary Figure S7. Immunohistochemical confirmation of target inhibition by rapamycin (p-S6) and dasatinib (p- Src ) in MMTV- PyMT tumor sections. Vehicle. Dasatinib. Rapamycin. Combination. H&E. 5 mm. p-S6. p- Src.

146 views • 1 slides

Supplementary Figure S8

Supplementary Figure S8. Dasatinib inhibits lung metastases in MMTV- PyMT tumor-bearing mice. #. *. *.

111 views • 1 slides

OLGU SUNUMU

OLGU SUNUMU. Dr.Özlem Özdemir Kumbasar. Çıkar çatışmam yoktur. 55 yaşında erkek hasta 1990 yılında KML tanısı almış Hydrea IFN ARA-C İmatinib Dasatinib Nilotinib

1k views • 48 slides

42.8%

Dasatinib + etoposide. 0.1μM dasatinib. 0.1μM Eto. Control. With DEAB. Without DEAB. The proportion of ALDH1-positive. 24.4%. 42.8%. 38.5%. 43.1%.

123 views • 1 slides

3.49%

Dasatinib + etoposide. 0.1μM dasatinib. 0.1μM Eto. Control. With DEAB. Without DEAB. The proportion of ALDH1-positive. 5.25%. 3.49%. 7.81%. 3.29%.

120 views • 1 slides

ASCO 2010, Abstract # LBA6500

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve-month Efficacy and Safety from the Phase 3 DASISION Study

530 views • 25 slides

Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve-Month Efficacy and Safety from the Phase III DASISION Study. Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

318 views • 7 slides

Shah N et al. Proc ASH 2010;Abstract 206.

Dasatinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the DASISION Trial: 18-Month Follow-Up. Shah N et al. Proc ASH 2010;Abstract 206. DASISION Study Schema. Dasatinib 100mg PO QD (n = 259). R. Imatinib 400mg PO QD

373 views • 12 slides

Kantarjian H et al. Proc ASCO 2011;Abstract 6510.

Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION. Kantarjian H et al. Proc ASCO 2011;Abstract 6510. DASISION Study Design. Dasatinib 100 mg QD (n = 259). R. Follow-up. 5 yrs. Imatinib 400 mg QD (n = 260).

258 views • 8 slides

A Proposal for BMS-354825 (Dasatinib) in GIST

A Proposal for BMS-354825 (Dasatinib) in GIST. Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center. BMS-354825 (Dasatinib).

298 views • 16 slides

Figure S4

JURL-MK1 + dasatinib. JURL-MK1 + imatinib. MOLM-7 + dasatinib. MOLM-7 + imatinib. JURKAT + imatinib. HEL + imatinib. Figure S4.

90 views • 1 slides

Dasatinib ( nM ) 0 0 0.1 0.5 1 5

250K. 200K. Dasatinib (nM) 0 0 0.5 1 5 10 M-CSF - + + + + +. 88.6. WB: Phospho- FMS Y708 WB: FMS. 150K. 100K. 50K. 0. Dasatinib (nM) 0 0 0.5 1 5 10

105 views • 2 slides

CML SPIRIT 3 Steve O ’ Brien

CML SPIRIT 3 Steve O ’ Brien Northern Institute for Cancer Research Newcastle University Medical School. Newcastle, March 2013. Thank you!. www.spirit-cml.org. Imatinib vs Dasatinib. Acknowledgements. SPIRIT 1 study design. Randomised open label study 3 treatment arms

508 views • 33 slides

Next Generation TKIs and Small Molecule Inhibitors Jennifer R Brown, MD PhD Director, CLL Center

Next Generation TKIs and Small Molecule Inhibitors Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School October 24, 2014. Targeting Kinases in the BCR Pathway. Everolimus. Dasatinib. Fostamatinib.

900 views • 43 slides

Sprycel 140mg Tablets| Dasatinib | MHP

Sprycel 140mg tablet is used for the treatment for Chronic Myeloid Leukaemia, Recently diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase, Severe, increased, or myeloid or lymphoid blast phase Ph CML with resistance or intolerance to prior therapy including imatinib.

189 views • 18 slides

Dasatinib Tablets 50 mg Online from India - Dasakast

This Dasatinib Tablets 50 mg is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). Dasatinib Tablets 50 mg price at Emedkit is available at very low cost and is always available with us and is accessible throughout India and other countries in the globe. Visit us - https://emedkit.com/dasatinib-tablets-50mg.html

83 views • 7 slides

Buy Dasatinib Tablets – Anticancer Medicine

Dasatinib Tablets is used in the treatment of blood cancer ( Chronic myeloid leukaemia ). It is used in patients whose disease could not be treated with other medications for leaukaemia or who cannot take these medications beacause of side effects. Oddway International is provide Dasatinib Tablets for a reasonable price. Buy Dasatinib Tablets from Oddway International since it provides safe and reliable delivery of the ordered products, in a short time. https://www.oddwayinternational.com/generic/dasatinib-brands-in-india

112 views • 10 slides

More Related